14. LIFE BELOW WATER

Assenagon Asset Management S.A. Acquires 948747 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Defense World

Written by Amanda

Assenagon Asset Management S.A. Acquires 948747 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)  Defense World

Assenagon Asset Management S.A. boosted its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDXGet Rating) by 3,594.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 975,139 shares of the biotechnology company’s stock after acquiring an additional 948,747 shares during the quarter. Assenagon Asset Management S.A. owned 1.68% of Aldeyra Therapeutics worth $4,334,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in ALDX. Walleye Capital LLC bought a new position in Aldeyra Therapeutics in the 4th quarter valued at about $1,423,000. Stonepine Capital Management LLC bought a new position in Aldeyra Therapeutics in the 4th quarter valued at about $800,000. Knoll Capital Management LLC lifted its position in Aldeyra Therapeutics by 33.4% in the 4th quarter. Knoll Capital Management LLC now owns 759,405 shares of the biotechnology company’s stock valued at $3,038,000 after acquiring an additional 190,000 shares in the last quarter. Dupont Capital Management Corp lifted its position in Aldeyra Therapeutics by 154.2% in the 4th quarter. Dupont Capital Management Corp now owns 162,134 shares of the biotechnology company’s stock valued at $649,000 after acquiring an additional 98,348 shares in the last quarter. Finally, Woodstock Corp bought a new position in Aldeyra Therapeutics in the 1st quarter valued at about $316,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.

In related news, CEO Todd C. Brady purchased 17,700 shares of the firm’s stock in a transaction dated Thursday, June 23rd. The stock was bought at an average price of $3.36 per share, for a total transaction of $59,472.00. Following the purchase, the chief executive officer now directly owns 1,216,535 shares in the company, valued at approximately $4,087,557.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 6.90% of the company’s stock.

Several research firms have commented on ALDX. StockNews.com began coverage on shares of Aldeyra Therapeutics in a research report on Thursday, March 31st. They set a “sell” rating on the stock. Citigroup lifted their target price on shares of Aldeyra Therapeutics from $21.00 to $26.00 and gave the stock a “buy” rating in a research report on Thursday, June 9th. Berenberg Bank began coverage on shares of Aldeyra Therapeutics in a research report on Tuesday, May 24th. They set a “buy” rating and a $28.00 target price on the stock. Oppenheimer lifted their target price on shares of Aldeyra Therapeutics to $11.00 in a research report on Thursday, June 9th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Aldeyra Therapeutics in a research report on Wednesday, April 27th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $19.00.

Shares of ALDX stock opened at $4.49 on Monday. The company has a 50 day moving average of $3.23 and a 200-day moving average of $3.75. The company has a debt-to-equity ratio of 0.08, a quick ratio of 13.60 and a current ratio of 13.60. Aldeyra Therapeutics, Inc has a 12-month low of $2.36 and a 12-month high of $10.90.

Aldeyra Therapeutics (NASDAQ:ALDXGet Rating) last issued its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.02. During the same quarter in the previous year, the business posted ($0.25) EPS. On average, sell-side analysts forecast that Aldeyra Therapeutics, Inc will post -1.37 EPS for the current year.

Aldeyra Therapeutics Profile (Get Rating)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.

Read More

Institutional Ownership by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aldeyra Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Source: defenseworld.net

About the author

Amanda

Hi there, I am Amanda and I work as an editor at impactinvesting.ai;  if you are interested in my services, please reach me at amanda.impactinvesting.ai

Leave a Comment